Pharsight

1. List of Xpovio drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9714226	KARYOPHARM THERAPS	Hydrazide containing nuclear transport modulators and uses thereof	Jul, 2032 (9 years from now)
US8999996	KARYOPHARM THERAPS	Hydrazide containing nuclear transport modulators and uses thereof	Sep, 2032 (9 years from now)
US10519139	KARYOPHARM THERAPS	Polymorphs of Selinexor	Aug, 2035 (12 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079865	KARYOPHARM THERAPS	Hydrazide containing nuclear transport modulators and uses thereof	Jul, 2032 (9 years from now)
US10544108	KARYOPHARM THERAPS	Hydrazide containing nuclear transport modulators and uses thereof	Jul, 2032 (9 years from now)
US11034660	KARYOPHARM THERAPS	Hydrazide containing nuclear transport modulators and uses thereof	Jul, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Jun 22, 2027
New Chemical Entity Exclusivity (NCE)	Jul 3, 2024
New Indication (I)	Jun 22, 2023

NCE-1 date: July, 2023

Market Authorisation Date: 03 July, 2019

Treatment: Xpovio is indicated in combination with dexamethasone to treat relapsed or refractory multiple myeloma (refractory to at least an anti-cd38 mab, 2 proteasome inhibitors and 2 immunomodulatory agents) in adults who received at least 4 prior therapies; Xpovio is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl), not otherwise specified, including dlbcl arising from follicular lymphoma, after at least 2 lines of systemic therapy; Xpovio is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

Dosage: TABLET;ORAL